Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference
LEXINGTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”)…
Helport AI Advances Transition to Autonomous AI Labor in Southeast Asian Fintech Market